Read More
Mabwell (Shanghai) Bioscience's retail tranche for its Hong Kong initial public offering was 26.8 times oversubscribed on Tuesday.
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
It has drawn HK$4.02 billion in margin loans.
Chinese biopharmaceutical company plans to offer 47.13 million H shares at between HK$27.64 and HK$30.71 per share, raising at most HK$1.45 billion. It asks for a minimum investment of HK$6,204 per board lot of 200 shares.
The company is expected to debut on April 28.
